Document:

EX-10.1

 Exhibit 10.1 

REGISTRATION RIGHTS AGREEMENT 

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), is made as of the 29 day of January, 2021, by and among United
Medicines Biopharma Limited, a private company limited by shares incorporated in England with company number 12973576 and with its registered office at The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, United Kingdom, CB22
3FH (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”. Capitalized terms used but not defined herein shall have the
meanings ascribed to them in the Subscription Agreement (as defined below). 
 RECITALS 

WHEREAS, the Company and the Investors are parties to a certain Subscription Agreement relating to the Company of even date
herewith (the “Subscription Agreement”); and 
 WHEREAS, in order to induce the Company to enter into the
Subscription Agreement and to induce the Investors to invest funds in the Company pursuant to the Subscription Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the
Company to register (i) the Ordinary Shares of the Company (“Ordinary Shares”) underlying the A Preferred Shares to be issued pursuant to the Subscription Agreement and (ii) the other Ordinary Shares held by the Investors
party hereto, and shall govern certain other matters as set forth in this Agreement; 
 NOW, THEREFORE, the parties hereby agree as
follows: 
 1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, in relation to a person, any corporation or other business entity that, directly or
indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such person or any venture capital fund or any other investment fund now or hereafter existing that is controlled by or under common control
with one or more general partners or managing members of, or shares the same management or advisory company with, such person. For purposes of this definition, the term “ control” (including, the correlative meanings,
“controlled by” and “under common control with”) means: 
  

	 	(a)	 the direct or indirect ownership of more than 50% of the stock having the right to vote for directors thereof
(or general partnership interests); or 

  

	 	(b)	 the ability to otherwise control the decisions of the board of directors or equivalent governing body thereof
or direct or cause the direction of the management and policies thereof. 

 1.2 “Articles of
Association” means the Company’s Articles of Association, as amended and/or restated from time to time. 
 1.3
“Board of Directors” means the board of directors of the Company. 
 1.4 “Damages” means
any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect
thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein
or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged
violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities
law. 

 1.5 “Exchange Act” means the Securities Exchange Act of
1934, as amended, and the rules and regulations promulgated thereunder. 
 1.6 “Excluded Registration” means
(i) a registration relating to the sale or grant of securities to employees or consultants of the Company or a subsidiary pursuant to a share option, share purchase, equity incentive or similar plan; (ii) a registration relating to an SEC
Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a
registration in which the only Ordinary Shares being registered are Ordinary Shares issuable upon conversion of debt securities that are also being registered. 

1.7 “Form S- 1” means such form under the Securities Act as in effect
on the date hereof (or the foreign private issuer equivalent Form F-1) or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.8 “Form S- 3” means such form under the Securities Act as in effect
on the date hereof (or the foreign private issuer equivalent Form F-3) or any registration form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 
 1.9 “Holder” means any
holder of Registrable Securities who is a party to this Agreement. 
 1.10 “Immediate Family Member” means a
child, stepchild, grandchild, parent, stepparent, grandparent, spouse, life partner or similar statutorily recognized domestic partner, sibling, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.11 “ Initiating Holders” means, collectively, Holders who properly initiate a registration request under
this Agreement. 
 1.12 “IPO” means the Company’s first underwritten public offering of its Ordinary
Shares under the Securities Act. 
 1.13 “Ordinary Shares” shall have the meaning set forth in the Recitals.

 1.14 “Person” means any individual, corporation, partnership, trust, limited liability company,
association or other entity. 
 1.15 “Preferred Shares” or “A Preferred Shares” means A
preferred shares of £0.001 each in the capital of the Company from time to time. 
 1.16 “Registrable
Securities” means (i) the Ordinary Shares issuable or issued upon conversion of the Preferred Shares; (ii) any Ordinary Shares, or any Ordinary Shares issued or issuable (directly or indirectly) upon conversion and/or exercise of
any other securities of the Company, held by the Investors on the date hereof or acquired by the Investors after the date hereof; and (iii) any Ordinary Shares issued as (or issuable upon the conversion or exercise of any warrant, right, or
other security that is issued as) a dividend or other distribution with respect to, or 

  
 2 

 in exchange for or in replacement of, the shares referenced in clauses (i) and
(ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Subsection 3.1, and excluding for purposes of
Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

1.17 “Registrable Securities then outstanding” means the number of shares determined by adding the number of
outstanding Ordinary Shares that are Registrable Securities and the number of Ordinary Shares issuable (directly or indirectly) that are Registrable Securities pursuant to then exercisable and/or convertible securities. 

1.18 “Restricted Securities” means the securities of the Company required to be notated with the legend set
forth in Subsection 2.12(b) hereof. 
 1.19 “SEC” means the Securities and Exchange Commission. 

1.20 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.21 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.22 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.23 “Selling Expenses” means all underwriting discounts, selling commissions, and share
transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Subsection
2.6. 
 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) 4 years after the date of this
Agreement or (ii) 180 days after the effective date of the registration statement for the IPO, the Company receives a written request from Holders of a majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to at least 40% of the Registrable Securities then outstanding (or a lesser percentage if the anticipated aggregate offering price, net of Selling Expenses, would exceed $10
million), then the Company shall (x) within 10 days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in
any event within 60 days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating
Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand
Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 
 (b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least 10% of the Registrable
Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of

  
 3 

 
Selling Expenses, of at least $4 million, then the Company shall (i) within 10 days after the date such request is given, give a Demand Notice to all Holders other than the Initiating
Holders; and (ii) as soon as practicable, and in any event within 45 days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act
covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within 20 days of the date the Demand Notice is given, and in each case, subject
to the limitations of Subsections 2.1(c) and 2.3. 
 (c) Notwithstanding the foregoing obligations, if the Company furnishes
to Holders requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board of Directors it would be materially detrimental to
the Company and its shareholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially
interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving
as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with
respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than 90 days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more
than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other shareholder during such 90 day period other than an Excluded Registration.

 (d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection
2.1(a) (i) during the period that is 60 days before the Company’s good faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, a Company-initiated registration, provided that
the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a); or
(iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b). The
Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is 30 days before the Company’s good faith estimate of the date of filing of, and
ending on a date that is 90 days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become
effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as
“effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not
to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of
this Subsection 2.1(d); provided, that if such withdrawal is during a period the Company has deferred taking action pursuant to Subsection 2.1(c), then the Initiating Holders may withdraw their request for registration and such
registration will not be counted as “effected” for purposes of this Subsection 2.1(d). 
 (e) The rights of an Initiating
Holder, or any of its successors or assigns, to request registration pursuant to this Subsection 2.1 shall encompass, at such Initiating Holder’s reasonable discretion, registration on a foreign exchange, with the provisions in this
Section 2 applying, mutatis mutandis, to such registration. 

  
 4 

 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for shareholders other than the Holders) any of its Ordinary Shares under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration or in the IPO), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within 20 days after such notice is given by the Company, the Company shall, subject to the
provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such
withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 
 2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and
shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting; provided, however that no Holder shall be required to make any representations,
warranties or indemnities except as they relate to such Holder’s ownership of shares and authority to enter into the underwriting agreement and to such Holder’s intended method of distribution. Notwithstanding any other provision of this
Subsection 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating
Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number
of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above
provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 
 (b) In
connection with any offering involving an underwriting of shares of the Company’s share capital pursuant to Subsection 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting
unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by
the Company. If the total number of securities, including Registrable Securities, requested by shareholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their
reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the
Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the
Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as
shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may 

  
 5 

 
round the number of shares allocated to any Holder to the nearest 100 shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the
offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below 25% of the
total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other shareholder’s securities
are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners,
retired members, shareholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be
deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling
Holder,” as defined in this sentence. 
 (c) For purposes of Section 2.1, a registration shall not be counted
as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in
such registration statement are actually included. 
 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to 120 days or, if
earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such 120 day period shall be extended for a period of time equal to the period a Holder refrains, at the
request of an underwriter of Ordinary Shares (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such 120 day period shall be extended for up to 60 days, if necessary, to keep the registration
statement effective until all such Registrable Securities are sold; 
 (b) prepare and file with the SEC such amendments and supplements to
such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;

 (c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the
Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

  
 6 

 (e) in the event of any underwritten public offering, enter into and perform its
obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f) use its
commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which
similar securities issued by the Company are then listed; 
 (g) provide a transfer agent and registrar for all Registrable Securities
registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to
such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the
accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 
 (i) notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; 

(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus; and 
 (k) notify each selling Holder at any time (should a prospectus relating to
such registration statement be required to be delivered) of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state
a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing, and, at the request of any such Holder, the Company will, as soon as reasonably practicable,
file and furnish to all such Holders a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus will not contain an untrue statement of a material fact or omit to
state any fact necessary to make the statements therein not misleading in light of the circumstances under which they were made. 
 In
addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the
Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 

2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

  
 7 

 2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in
connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the
Company; and the reasonable fees and disbursements, not to exceed $50,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company
shall not be required to pay for any expenses of any registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to
be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable
Securities agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a
material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders
shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this
Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and shareholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be
liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or
other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each selling
Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the
Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending
any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such
claim or proceeding if such settlement is effected 

  
 8 

 
without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way
of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such
Holder. 
 (c) Promptly after receipt by an indemnified party under this Subsection 2.8 of notice of the commencement of any action
(including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Subsection 2.8, give the
indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which
notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without
conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be
inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the indemnifying party within a reasonable time of the
commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend
such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Subsection 2.8. 

(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for indemnification in such case, or
(ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will contribute to the aggregate
losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in
connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the
indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case
(x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no
event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net
of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the
foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions
in the underwriting agreement shall control. 
  

  
 9 

 (f) Unless otherwise superseded by an underwriting agreement entered into in connection
with the underwritten public offering, the obligations of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this
Section 2, and otherwise shall survive the termination of this Agreement or any provision(s) of this Agreement. 

2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or
regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to file with
the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time
after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would provide to such holder or prospective holder the
right (a) to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the registration and
offering all shares of Registrable Securities that they wish to so include or (b) to demand registration of their securities; provided that this limitation shall not apply to Registrable Securities acquired by any additional Investor
that becomes a party to this Agreement in accordance with Subsection 3.9. 
 2.11 “Market
Stand-off” Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus
relating to the registration by the Company of its Ordinary Shares or any other equity securities under the Securities Act on a registration statement on Form S-1 relating to the Company’s IPO, and ending
on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or
contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any Ordinary Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for
Ordinary Shares held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of such securities, whether any such transaction described in clause (i) or (ii) 

  
 10 

 
above is to be settled by delivery of Ordinary Shares or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall not apply to
(i) the sale of any shares (x) to an underwriter pursuant to an underwriting agreement, (y) acquired by a Holder in the Company’s IPO or (z) acquired by a Holder in the secondary market following the IPO or (ii) the
establishment of a trading plan pursuant to Rule 10b5-1, provided that such trading plan does not permit transfers during the restricted period, and shall be applicable to the Holders only if all
officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding
Ordinary Shares (after giving effect to conversion into Ordinary Shares of all outstanding Preferred Shares). The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11
and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such
registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. 

2.12 Restrictions on Transfer. 

(a) The Preferred Shares and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except in accordance with the Articles of Association and/or the Subscription Agreement and upon the conditions specified
in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Shares and the Registrable Securities
held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

(b) Each certificate, instrument, or book entry representing (i) the Preferred Shares, (ii) the Registrable Securities, and
(iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any share split, share dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the
provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 
 THE SECURITIES REPRESENTED HEREBY
HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE OFFERED, SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND
PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 
 THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN
AGREEMENT BETWEEN THE COMPANY AND THE SHAREHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to
the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall
give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably

  
 11 

 
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably
satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed
sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel
to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon, subject to the provisions of the Articles of Association and/or the
Subscription Agreement, the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require
such a notice, legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no
consideration; provided that each transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall
be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive
legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any
registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of: 
 (a) the closing of a Share
Sale, as such term is defined in the Articles of Association; 
 (b) such time after consummation of the IPO as Rule 144 or another similar
exemption under the Securities Act is available for the sale of all of such Holder’s Registrable Securities without limitation during a three-month period without registration; and 

(c) the fourth anniversary of the IPO. 
  

	 	3.	 Miscellaneous. 

3.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i) is an Affiliate of a Holder; or (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members;
provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights
are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the
purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or shareholder of a Holder; (2) who is a Holder’s Immediate Family Member; or
(3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not
qualify individually for assignment of rights shall, as a condition to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any
rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this
Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as
expressly provided herein. 

  
 12 

 3.2 Governing Law. This Agreement shall be governed by the internal law of the State
of Delaware, without regard to conflict of law principles that would result in the application of any law other than the law of the State of Delaware. 

3.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

3.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 3.5 Notices. 

(a) All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business
hours, then on the recipient’s next business day; (iii) five (5) business days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) three (3) business days after the business day
of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at
their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as
subsequently modified by written notice given in accordance with this Subsection 3.5. If notice is given to the Company, a copy shall also be sent to at The Dorothy Hodgkin Building, Babraham Research Campus, Babraham, Cambridge, United
Kingdom, CB22 3FH, and Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210, Attention: Mitch Bloom. 
 (b) Consent to
Electronic Notice. Each Investor consents to the delivery of any shareholder notice by electronic transmission at the electronic mail address or the facsimile number provided in Schedule A. Each Investor agrees to promptly notify the
Company of any change in such shareholder’s electronic mail address, and that failure to do so shall not affect the foregoing. 
 3.6
Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively)
only with the written consent of the Company and the Holders of a majority of the Registrable Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the
Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be
waived by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended, modified or terminated and the observance of any term hereof may not be waived
with respect to any Investor without the written consent of such Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion. Notwithstanding the foregoing, Schedule A hereto may be
amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms of this Agreement without the consent of the other parties; and Schedule A hereto may also be

  
 13 

 
amended by the Company after the date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party to this Agreement in
accordance with Subsection 3.9. Any amendment, modification, termination, or waiver effected in accordance with this Subsection 3.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No
waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

3.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 
 3.8 Aggregation of Shares. All shares of Registrable Securities held
or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 3.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional Preferred
Shares after the date hereof, whether pursuant to the Subscription Agreement or otherwise, any purchaser of such Preferred Shares may become a party to this Agreement by executing and delivering an additional counterpart signature page to this
Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor
has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 
 3.10 Entire Agreement. This
Agreement (including any Schedules hereto) together with the other agreements entered into in connection with the investment constitute the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and
any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 
 3.11
Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state and federal courts of Kent County in the State of Delaware for the purpose of any suit, action or other proceeding arising
out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state or federal courts of Kent County in the State of Delaware, and (c) hereby
waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune
from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. 
 Each party will bear its own costs in respect of any disputes arising under this Agreement. The prevailing party shall be entitled
to reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in
the state or federal courts of Kent County in the State of Delaware. 

  
 14 

 3.12 Delays or Omissions. No delay or omission to exercise any right, power, or
remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a
waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

[Remainder of Page Intentionally Left Blank] 

  
 15 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
  

					
	COMPANY:	 		 	
			
	SIGNED by	 	)	 	
	 UNITED MEDICINES BIOPHARMA

LIMITED
	 	 )
 )
	 	
	acting by a director	 	)	 	 /s/ Richard Lee

			
	        Richard Lee	 		 	

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

 667, L.P. 

BY: BAKER BROS. ADVISORS LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech
Capital, L.P., general partner to 667, L.P., and not as the general partner. 
  

			
	 By:
	 	 /s/ Scott Lessing

	 Scott Lessing

	 President

 BAKER BROTHERS LIFE SCIENCES, L.P. 

By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it
by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner. 
  

			
	 By:
	 	 /s/ Scott Lessing

	 Scott Lessing

	 President

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

			
	 BOXER CAPITAL, LLC

		
	 By:
	 	 /s/ Aaron Davis

	 Aaron Davis

	 Chief Executive Officer

	
	 MVA INVESTORS, LLC

		
	 By:
	 	 /s/ Aaron Davis

	 Aaron Davis

	 Chief Executive Officer

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

			
	 BIOTECHNOLOGY VALUE FUND, L.P.

		
	 By:
	 	 /s/ Mark Lampert

	 Name:
	 	 Mark Lampert

	Title:	 	Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P.
	
	 BIOTECHNOLOGY VALUE FUND II, L.P.

		
	 By:
	 	 /s/ Mark Lampert

	 Name:
	 	 Mark Lampert

	Title:	 	Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P.
	
	BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.
		
	 By:
	 	 /s/ Mark Lampert

	 Name:
	 	 Mark Lampert

	Title:	 	President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.

  

SIGNATURE PAGE TO
REGISTRATION RIGHTS AGREEMENT 

	
	/s/ Bihua Chen
	CORMORANT PRIVATE HEALTHCARE FUND III, LP
	 By: Cormorant Private Healthcare GP III, LLC

	 By: Bihua Chen, Managing Member

	
	/s/ Bihua Chen
	CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
	 By: Cormorant Global Healthcare GP, LLC

	 By: Bihua Chen, Managing Member

	
	/s/ Bihua Chen
	CRMA SPV, L.P.
	 By: Cormorant Asset Management, LP

	 By: Bihua Chen,
Attorney-in-fact

  

SIGNATURE PAGE TO
REGISTRATION RIGHTS AGREEMENT 

			
	ECOR1 CAPITAL FUND, L.P.
	
	By: EcoR1 Capital, LLC, its General Partner
		
	By:	 	/s/ Oleg Nodelman
	Name:	 	Oleg Nodelman,
	Title:	 	Manager
	
	ECOR1 CAPITAL FUND QUALIFIED, L.P.
	
	By: EcoR1 Capital, LLC, its General Partner
		
	By:	 	/s/ Oleg Nodelman
	Name:	 	Oleg Nodelman,
	Title:	 	Manager
	
	ECOR1 VENTURE OPPORTUNITY FUND, L.P.
	
	By: Biotech Opportunity GP, LLC, its General Partner
		
	By:	 	/s/ Oleg Nodelman
	Name:	 	Oleg Nodelman,
	Title:	 	Manager

  

SIGNATURE PAGE TO
REGISTRATION RIGHTS AGREEMENT 

			
	FRANKLIN TEMPLETON INVESTMENT FUNDS – FRANKLIN BIOTECHNOLOGY DISCOVERY FUND
	
	 By: Franklin Advisers, Inc., as investment
manager

			
		
	 By:
	 	 /s/ Evan
McCulloch

			
	 Evan McCulloch

	 Vice President

	
	FRANKLIN STRATEGIC SERIES – FRANKLIN BIOTECHNOLOGY DISCOVERY FUND
	
	 By: Franklin Advisers, Inc., as investment
manager

			
		
	 By:
	 	 /s/ Evan
McCulloch

			
	 Evan McCulloch

	 Vice President

  

SIGNATURE PAGE TO
REGISTRATION RIGHTS AGREEMENT 

									
	GENERAL ATLANTIC UM B.V.	 		 	
			
	 /s/ Ingrid van der Hoorn
	 		 	 /s/ Wolbert Kamphuijs

	By:	 	Ingrid van der Hoorn	 		 	By:	 	Wolbert Kamphuijs
	Title:	 	Director A	 		 	Title:	 	Director B

 g.B. 

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

			
	JANUS HENDERSON GLOBAL LIFE SCIENCES FUND
	
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

	Name:	 	Andrew Acker
	Title:	 	Authorized Signatory
	
	JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED
	
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

	Name:	 	Andrew Acker
	Title:	 	Authorized Signatory
	
	JANUS HENDERSON CAPITAL FUNDS PLC ON BEHALF OF ITS SERIES JANUS HENDERSON GLOBAL LIFE SCIENCES FUND
	
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

	Name:	 	Andrew Acker
	Title:	 	Authorized Signatory

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

			
	JANUS HENDERSON HORIZON FUND - BIOTECHNOLOGY FUND
	
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

	Name:	 	Andrew Acker
	Title:	 	Authorized Signatory
	
	JANUS HENDERSON VENTURE FUND
	
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Jonathan Coleman

	Name:	 	Jonathan Coleman
	Title:	 	Authorized Signatory

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

			
	LIFESCI VENTURE PARTNERS II, LP
		
	By:	 	 /s/ Paul Yook

	Name:	 	Paul Yook
	Title: Managing Member
	
	LIFESCI VENTURE MASTER SPV, LLC
		
	By:	 	 /s/ Paul Yook

	Name:	 	Paul Yook
	Title:	 	Managing Member

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

			
	LOGOS OPPORTUNITIES FUND II, L.P.
	
	By: Logos Opportunities GP, LLC
	Its General Partner
		
	By:	 	 /s/ Graham Walmsley

	Name:	 	Graham Walmsley
	Title:	 	Managing Member
		
	By:	 	 /s/ Arsani William

	Name:	 	Arsani William
	Title:	 	Managing Partner

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

							
	SIGNED for and on behalf of	  	)	  		  	
	MEDICXI GROWTH I LP	  	)	  		  	
	by its manager MEDICXI VENTURES 	  	)	  		  	
	MANAGEMENT (JERSEY) LIMITED	  	)	  	 /s/ Andrew Jeanne

		  		  	Andrew Jeanne	  	Director
				
	SIGNED for and on behalf of	  	)	  		  	
	MEDICXI GROWTH CO-INVEST I LP	  	)	  		  	
	by its manager MEDICXI VENTURES 	  	)	  		  	
	MANAGEMENT (JERSEY) LIMITED	  	)	  	 /s/ Andrew Jeanne

		  		  	Andrew Jeanne	  	Director
				
	Signed for and on behalf of	  	)	  		  	
	MEDICXI VENTURES I LP	  	)	  		  	
	By: its manager MEDICXI VENTURES 	  	)	  	 /s/ Andrew Jeanne

	MANAGEMENT (JERSEY) LIMITED	  	)	  	Andrew Jeanne	  	Director
				
	Signed for and on behalf of	  	)	  		  	
	MEDICXI CO-INVEST I LP	  	)	  		  	
	By: its manager MEDICXI VENTURES 	  	)	  	 /s/ Andrew Jeanne

	MANAGEMENT (JERSEY) LIMITED	  	)	  	Andrew Jeanne	  	Director
				
	Signed for and on behalf of	  	)	  		  	
	MEDICXI SECONDARY I LP	  	)	  		  	
	By: its manager MEDICXI VENTURES 	  	)	  	 /s/ Andrew Jeanne

	MANAGEMENT (JERSEY) LIMITED	  	)	  	Andrew Jeanne	  	Director
				
	Signed for and on behalf of	  	)	  		  	
	MEDICXI SECONDARY CO-INVEST I LP	  	)	  		  	
	By: its manager MEDICXI VENTURES 	  	)	  	 /s/ Andrew Jeanne

	MANAGEMENT (JERSEY) LIMITED	  	)	  	Andrew Jeanne	  	Director

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

							
	Executed as a deed for and on behalf of	  	)	  		  	
	INDEX VENTURES LIFE VI (JERSEY), L.P.	  	)	  	 /s/ Sarah Earles

	By: its Managing General Partner:	  	)	  	and/or
	Index Venture Life Associates VI Limited	  	)	  	Director	  	                        Director
		  		  	Sarah Earles	  	

  

					
	Executed as a deed for and on behalf of	  	)	  	 /s/ Sarah Earles         /s/ Andrew Le Couilliard

	YUCCA (JERSEY) SLP	  	)	  	Sarah Earles             Andrew Le Couilliard
	By: Intertrust Employee Benefit Services Limited	  	)	  	Authorised Signatory - Intertrust Employee
	as Authorised Signatory of Yucca (Jersey) SLP in	  	)	  	Benefit Services Limited
	its capacity as administrator of the Index Life Co-	  		  	
	Investment Scheme	  		  	
			
	Executed by MEDICXI (MG1) S.A.R.L.,	  	)	  	 /s/ Giles Johnstone Scott

	acting by: Mr. Giles Johnstone Scott	  	)	  	Signature
	and Mr. Anthony Agostino	  	)	  	
		  	)	  	
		  	)	  	
		  	)	  	 /s/ Anthony Agostino

		  		  	Signature
			
	Executed by MEDICXI (MV1) S.A.R.L.,	  	)	  	 /s/ Giles Johnstone Scott

	acting by: Mr. Giles Johnstone Scott	  	)	  	Signature
	and Mr. Anthony Agostino	  	)	  	
		  	)	  	
		  	)	  	
		  	)	  	 /s/ Anthony Agostino

		  		  	Signature

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

					
	Executed by	  	)	  	
	Srinivas Akkaraju	  	)	  	
		  	)	  	 /s/ Srinivas Akkaraju

	Samsara BioCapital, L.P.	  		  	Signature
			
	acting by: SAMSARA BIOCAPITAL GP, LLC 	  		  	
			
	Position: Managing Member	  		  	

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

			
	T. ROWE PRICE HEALTH SCIENCES FUND, INC.
	
	TD MUTUAL FUNDS - TD HEALTH SCIENCES FUND
	
	T. ROWE PRICE HEALTH SCIENCES PORTFOLIO
	
	Each account, severally and not jointly
	
	By: T. Rowe Price Associates, Inc., Investment Adviser or Subadviser, as applicable
		
	By:	 	 /s/ Andrew Baek

	Name: Andrew Baek
	Title: Vice President

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

			
	VENROCK HEALTHCARE CAPITAL PARTNERS EG, L.P.
	By:	 	VHCP Management EG, LLC, its general partner
		
	By:	 	  

		 	Authorized Signatory
	
	VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P.
	By:	 	VHCP Management III, LLC, its general partner
	By:	 	VR Advisor, LLC, its manager
	
	VHCP CO-INVESTMENT HOLDINGS III, LLC
	By:	 	VHCP Management III, LLC, its manager
	By:	 	VR Advisor, LLC, its manager
		
	By:	 	  

		 	Authorized Signatory

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

			
	VIDA VENTURES II, LLC
	
	By: VV Manager II LLC, its Managing Member
		
	By:	 	 /s/ Arjun Goyal

	Name: Arjun Goyal
	Title: Managing Director
	
	VIDA VENTURES II-A, LLC
	
	By: VV Manager II LLC, its Managing Member
		
	By:	 	 /s/ Arjun Goyal

	Name: Arjun Goyal
	Title: Managing Director

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENT

			
	WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.
		
	By:	 	Wellington Management Company LLP, as investment adviser

  

			
	By:	 	 /s/ Peter N. McIsaac

	Name:	 	Peter N. McIsaac
	Title:	 	Managing Director and Counsel

  

SIGNATURE PAGE TO REGISTRATION RIGHTS AGREEMENTEX-10.5

 Exhibit 10.5 

Saurabh Saha, MD, PhD 
 November 19, 2020,
revised on December 2, 2020 
  

	Re:	 Offer of Employment 

Dear Saurabh: 
 On behalf of United Medicines, I am pleased to
confirm our offer to employ you as Chief Executive Officer. United Medicines Biopharma Limited (“Parent”) is a to-be-formed U.K. corporation that will
be the parent company of a subsidiary that will be formed in the United States (the “U.S. Subsidiary”). Parent, the U.S. Subsidiary and their respective subsidiaries and other affiliates are collectively referred to herein as
“United Medicines” or the “Company,” and the duties of the Company set forth in this Agreement may be discharged by any entity within that definition. The initial terms and conditions of your employment, should you
accept this offer, are set forth below in this letter agreement (the “Agreement”): 
 1. Position. As Chief
Executive Officer of the Company, you will have such powers and duties as may from time to time be prescribed by Parent’s Board of Directors (the “Board”). The U.S. Subsidiary will maintain and distribute employment-related
records. You shall serve on the Board for so long as you remain the Chief Executive Officer of the Company; provided that to the extent the Company becomes a public company, the Company’s obligation with respect to such Board service
shall be limited to the Company causing you to be nominated for election to the Board and to be recommended to the stockholders for election to the Board; provided further, that you shall be deemed to have resigned from the Board and from any
related positions upon ceasing to serve as the Chief Executive Officer for any reason. This is a full-time employment position. It is understood and agreed that, while you render services to the Company, you will not engage in any other employment,
consulting or other business activities (whether full-time or part-time), except as expressly authorized in writing by the Board. Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such
activities do not interfere or conflict with your obligations to the Company. 
 2. Start Date. Your employment with the Company
will begin on a date to be mutually agreed to by you and the Company. For the avoidance of doubt, in no event will the Start Date be before the date that the U.S. Subsidiary is formed. The actual first day of your employment with the Company shall
be referred to herein as the “Start Date.” 
 3. Compensation and Related Matters. 

(a) Base Salary. The Company will pay you an initial base salary at the rate of $600,000 per year, payable in accordance with the
Company’s standard payroll schedule for its U.S. executives and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and adjustments at the Company’s discretion. Your base salary in effect
at any given time is referred to herein as the “Base Salary.” 

 (b) Annual Bonus. Commencing in calendar year 2021, you will initially be eligible to
receive an annual performance bonus targeted at 45% of your Base Salary and pro-rated based on your Start Date. The actual bonus amount is discretionary and will be determined by the Board or the Compensation
Committee thereof. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15th of the calendar
year following the calendar year to which such bonus relates. 
 (c) Sign-On Bonus. Within 30
days following the Start Date, the Company will pay you a one-time signing bonus in the amount of $100,000, less applicable tax-related deductions and withholdings (the
“Sign-On Bonus”); provided that if the Company terminates your employment for Cause (as defined in Appendix A) or you resign your employment for any reason other than for Good
Reason (as defined in Appendix A), in either case prior to the one (1) year anniversary of the Start Date, you will repay the full Sign-On Bonus within 10 days after the Date of Termination (as
defined below). 
 (d) Expenses. The Company will promptly reimburse you for all reasonable expenses incurred by you in performing
services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its U.S. executives. 

(e) Benefits/Paid Time Off. You will be eligible, subject to the terms of the applicable plans and programs, to participate in the
employee benefits and insurance programs generally made available to the Company’s full-time U.S. employees. Details of such benefits programs, including mandatory employee contributions, if any, and waiting periods, if applicable, will be made
available to you when such benefit(s) become available. You will be entitled to paid time off consistent with the terms of the Company’s paid time off policy for its U.S. executives, as in effect from time to time. The Company reserves the
right to modify, amend or cancel any of its benefits plans or programs at any time. 
 4. Equity Award. At such time as
Parent issues and sells shares of its capital stock in connection with the Series A Financing and subject to approval of the Board and your continued employment on the date of grant or issuance, Parent shall grant to you (at your option) either a
restricted stock award for a number of shares of Parent’s common stock (the “Restricted Shares”) or a stock option to purchase a number of shares of Parent’s common stock (the “Option”) equal to 5.0% of
Parent’s fully diluted capitalization (reflecting then outstanding capital stock and stock options) following such issuance and sale. The Restricted Shares or Option will be subject to the standard terms and conditions of Parent’s equity
incentive plan then in effect and the applicable equity award agreement (the “Equity Documents”), including with respect to vesting as follows: 25% of the Restricted Shares or Options shall vest on the first anniversary of the Start
Date (the “Vesting Commencement Date”) and the remainder shall vest in equal quarterly installments over the twelve (12) quarters thereafter, subject to your continued employment with the Company at each such vesting date, such
that the Restricted Shares or Option shall be fully vested upon the fourth (4th) anniversary of the Vesting Commencement Date. Notwithstanding anything to the contrary in the Equity Documents or in any applicable option agreement or other
stock-based award agreement, 100% of the unvested portion of the Restricted Shares or the Option, as applicable, as well as any future time-based equity awards that you may be granted in the Board’s sole discretion, shall immediately accelerate
and become fully exercisable or nonforfeitable as of the effective date of a Change in Control of Parent (as defined in Appendix A), provided that you remain employed on the effective date of such Change in Control of Parent. 

  
 2 

 In the event a Qualifying Termination (as defined in Appendix A) occurs within the fifteen
(15) month period immediately following the Start Date and you enter into the Separation Agreement and Release (as defined below) and it becomes irrevocable within 60 days after the Date of Termination (or such shorter period as set forth in
the Separation Agreement and Release), then, notwithstanding anything to the contrary in the Equity Documents, the unvested portion of the Restricted Shares or the Option, as applicable, that otherwise would have vested between the Date of
Termination and the fifteen (15) month anniversary of the Start Date if your employment had continued during such period shall immediately accelerate and become fully exercisable or nonforfeitable as of the later of (i) the Date of
Termination and (ii) the effective date of the Separation Agreement and Release (the “Accelerated Vesting Date”), provided that in order to effectuate the accelerated vesting contemplated by this paragraph, the unvested
portion of the Restricted Shares or the Option that is subject to acceleration pursuant to this paragraph that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A) the effective date of the Separation
Agreement and Release (at which time acceleration will occur), or (B) the date that the Separation Agreement and Release can no longer become fully effective (at which time the unvested portion of the Restricted Shares or the Option that is
subject to acceleration pursuant to this paragraph will be forfeited). Notwithstanding the foregoing, no additional time-based vesting of the Restricted Shares or the Option shall occur during the period between the Date of Termination and the
Accelerated Vesting Date. 
 5. Location. You initially will be permitted to work from your home office in Massachusetts, provided,
however, that you may be required to regularly travel to the U.K., France and Germany, and you may also be required to travel nationally and internationally on business as is necessary from time to time. During the
COVID-19 pandemic, such travel may be limited to essential travel and will be in accordance with applicable safety regulations. 

6. At-Will Employment; Date of Termination. At all times your employment is “at will,”
meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Your last day of employment for any reason is referred to herein as the “Date of Termination.” In the event that
you elect to end your employment other than for Good Reason, the Company requires you to provide at least 30 days’ advance written notice to the Company. Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of
Termination, and such acceleration shall not result in a termination by the Company for purposes of this Agreement. In the interest of clarity, any intercompany transfer between Parent, the U.S. Subsidiary and their respective subsidiaries and
affiliates shall not be deemed a termination of the employment relationship unless otherwise specified at the time of the transfer. 
 To the extent
applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall
execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. 

  
 3 

 7. Accrued Obligations. In the event of the ending of your employment for any reason, the
Company shall pay you (i) your Base Salary and, if applicable, any accrued but unused vacation, through the Date of Termination, and (ii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any
such termination and not yet reimbursed (the “Accrued Obligations”). 
 8. Severance Pay and Benefits Upon a Qualifying
Termination. In the event that a Qualifying Termination (as defined in Appendix A) occurs, then, in addition to you being entitled to the Accrued Obligations, and subject to (i) you signing a separation agreement and release in a
form and manner reasonably satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities, a reaffirmation of the Continuing Obligations (as defined below),
and a one year post-employment noncompetition agreement, and shall provide that if you breach the Continuing Obligations, all payments of the Severance Amount (as defined below) shall immediately cease (the “Separation Agreement and
Release”), (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven
(7) business day revocation period, and (iii) if so requested by the Company, you signing a U.K. settlement agreement: 
 (a) The
Company shall pay you an amount equal to twelve (12) months of your Base Salary (the “Severance Amount”); provided that in the event you are entitled to any payments pursuant to the Restrictive Covenants Agreement, the
Severance Amount received in any calendar year will be reduced by the amount you are paid in the same such calendar year pursuant to the Restrictive Covenants Agreement (the “Restrictive Covenants Agreement Setoff’); and 

(b) subject to your copayment of premium amounts at the applicable active employees’ rate and your proper election to receive benefits
under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay to the group health plan provider(s) or the COBRA provider a monthly payment equal to the monthly employer contribution
that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the twelve (12) month anniversary of the Date of Termination; (B) your eligibility for group
health plan benefits under any other employer’s group health plan; or (C) the cessation of your continuation rights under COBRA; provided, however, that if the Company reasonably determines that it cannot pay such amounts to the
group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to
payroll payments directly to you for the time period specified above. Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates;
and 
 The amounts payable under this Section 8, to the extent taxable, shall be paid out in substantially equal installments in accordance with the
Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second
calendar year, the Severance Amount, to the extent it qualifies as “non-qualified deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the
“Code”), shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury
Regulation Section 1.409A-2(b)(2). 

  
 4 

 If your employment ends for any reason other than a Qualifying Termination, you will be entitled to the
Accrued Obligations and will not be entitled to any further compensation from the Company. For the avoidance of doubt, if your employment ends due to your death or disability, you will receive the Accrued Obligations but will not be eligible for
severance pay and benefits, whether pursuant to this Section 8 or otherwise. 
 9. Continuing Obligations. 

(a) Restrictive Covenants Agreement. As a condition of your employment, you are required to enter into the Employee Confidentiality,
Assignment, Nonsolicitation and Noncompetition Agreement enclosed with this Agreement (the “Restrictive Covenants Agreement”). You acknowledge and agree that you are receiving the Restrictive Covenants Agreement with this Agreement
and at least ten (10) business days prior to the Start Date. For purposes of this Agreement, the obligations in this Section 9 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality,
assignment of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing Obligations.” 

(b) Third Party Agreements and Rights. You hereby confirm that you are not bound by the terms of any agreement with any previous
employer or other party which restricts your engagement in any business in any way, other than confidentiality restrictions (if any). You represent to the Company that your execution of this Agreement, your employment with the Company and the
performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any
agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or
obtained from any such previous employment or other party. You agree that, notwithstanding anything to the contrary herein, if your employment ends in connection with or as a result of a former employer or third party enforcing or attempting to
enforce a noncompetition obligation or other restrictive covenant against you, such termination will not constitute a Qualifying Termination for purposes of this Agreement. 

(c) Litigation and Regulatory Cooperation. During and after your employment, you shall cooperate fully with the Company in (i) the
defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were employed by the Company, and
(ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall include, but not
be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your employment, you also shall

  
 5 

 
cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or
occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with
your performance of obligations pursuant to this Section 9(c). 
 (d) Relief. You agree that it would be difficult to measure
any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose
to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving
any actual damage to the Company. 
 10. Section 409A 

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section
409A of the Code, the Company determines that you are a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or
otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section
409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash
payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of
the installments shall be payable in accordance with their original schedule. 
 (b) All in-kind benefits provided and expenses eligible for
reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any
reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind
benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to
liquidation or exchange for another benefit. 
 (c) To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits
shall be payable only upon your “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). 

  
 6 

 (d) The parties intend that this Agreement will be administered in accordance with Section
409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code.
Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as
reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either
party. 
 (e) The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of
this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

11. Legal Fees. The Company shall reimburse you for your reasonable attorneys’ fees incurred in the negotiation and execution of this Agreement,
subject to a maximum reimbursement of $5,000.00. 
 12. Withholding; Tax Effect. All forms of compensation referred to in this Agreement are subject
to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities,
and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation. 
 13. Interpretation and
Enforcement. This Agreement, together with Appendix A, the Restrictive Covenants Agreement and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company
and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. Except as expressly otherwise provided in the Equity Documents or the Restrictive Covenants Agreement, the terms
of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other
relationship between you and the Company (the “Disputes”) will be governed by Massachusetts law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction and venue of
the federal and state courts located in the Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute. 
 14.
Assignment; Successors and Assigns. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the
Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it
transfers all or substantially all of its properties or assets; provided further, that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall
not be entitled to any severance payments or 

  
 7 

 benefits solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding
upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns. In the event of your death after the Date of Termination but prior to the completion by the Company of all payments due
to you under this Agreement, the Company shall continue such payments to your beneficiary designated in writing to the Company prior to your death (or to your estate, if you fail to make such designation). 

15. Waiver; Amendment. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any
party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent
breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company. 

16. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this
Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so
declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

17. Conditions. This offer is contingent on the completion of successful reference and background checks, if so requested and as determined by the
Company. As with any employee, you must submit satisfactory proof of your identity and your legal authorization to work in the United States. 
 18.
Indemnification. You shall be entitled to indemnification with respect to your services provided hereunder to the fullest extent permissible pursuant to [Delaware] law, the Company’s By-Laws and/or charter, and the applicable Company
directors and officers (“D&O”) liability insurance policy that Company agrees to obtain within six (6) months after the Start Date. 

19. Other Terms. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the
extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this
Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals. 

[Signature page follows.] 

  
 8 

 To accept this offer of employment, please sign and return this Agreement and the Restrictive Covenants
Agreement to Jennifer Merrigan Fay, Esq at JFav@goodwinlaw.com by December 3, 2020. We look forward to your joining the Company. 
  

			
	 Very truly yours,

		
	By:	 	/s/ Richard Lee
	Richard Lee, Director
	
	Enclosure (Restrictive Covenants Agreement)
	
	I have read and accept this employment offer:
	
	 /s/ Saurabh Saha

	Saurabh Saha, MD, PhD
	
	Date: 12/10/20

 Appendix A 

 

	1)	 “Cause” shall mean (i) your dishonest statements or acts with respect to the Company or
any affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in harm to the Company; (ii) your
commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) your failure to perform your assigned duties and responsibilities to the reasonable satisfaction of the Board, which
failure continues, in the reasonable judgment of the Board, for thirty (30) days after written notice given to you describing such failure; (iv) your gross negligence, willful misconduct or insubordination that results in or is reasonably
anticipated to result in harm to the Company, which conduct, if curable, in the reasonable judgment of the Board, is not cured for more than thirty (30) days after written notice given to you describing such conduct; (v) your violation of
any material provision of any agreement(s) between you and the Company or any Company policies including, without limitation, this Agreement, agreements relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions or
policies related to ethics or workplace conduct, which violation, if curable, in the reasonable judgment of the Board, is not cured for more than (30) days after written notice given to you describing such violation; or (vi) your failure
to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Board to cooperate, or the willful destruction or failure to preserve documents or other materials
known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. 

 

	2)	 “Change in Control of Parent” shall mean “Change in Control” as that term is defined
in Parent’s equity incentive plan, to be adopted on or following the date of Parent’s formation. 

  

	3)	 “Good Reason” shall mean that you have complied with the “Good Reason Process”
(hereinafter defined) following the occurrence of any of the following events: (i) a material diminution in your responsibilities, authority or duties; (ii) a diminution in your Base Salary except for across-the-board salary reductions of similar magnitude based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company;
(iii) the material breach of this Agreement by the Company; or (iv) a relocation of your principal business location to a location more than seventy-five (75) miles from your current home in Wellesley, Massachusetts.

  

	4)	 “Good Reason Process” shall mean that (i) you reasonably determine in good faith that a
“Good Reason” condition has occurred; (ii) you notify the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) you cooperate in good faith with
the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and
(v) you terminate your employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

	5)	 “Qualifying Termination” shall mean, after the Start Date, the Company terminates your
employment without Cause or you resign from your employment for Good Reason. 

  
 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]